MET and scleroderma: Additionally, we demonstrated that antifibrotic effects mediated by the HGF receptor, also known as cellular mesenchymal-epithelial transition factor (c-MET, MET), are impaired in lung fibroblasts isolated from a subset of scleroderma patients with severe ILD suggesting a potential link between SSc-ILD and MET dysfunction [10].